- Home
- Companies
- Vedanta Biosciences, Inc
- Products
- Leveraging Breakthrough Discoveries in ...
Leveraging Breakthrough Discoveries in Immunology
From Ruslan Medzhitov`s discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman`s efforts to identify and clone CD4 and CD8, molecules on the surface of T cells that are crucial to immune recognition and response, Vedanta`s scientific co-founders have pioneered the current understanding of how the immune system recognizes and responds to microbes.
Recent work from Kenya Honda, Dan Littman, Brett Finlay, Ruslan Medzhitov, and Alexander Rudensky, has led to the realization that gut microbes are required for stimulation of a range of immune responses, including among others, making Th17 and regulatory T cells (Tregs), and thus are potentially useful as immunotherapies. Our co-founders` peer-reviewed and independently reproduced discoveries are the scientific foundation of our programs.
In the near future, your doctor may prescribe you drugs made of live bacterial consortia. These drugs have the potential of colonizing the human intestine naturally and repairing microbiome alterations that drive disease.
Why bacterial consortia?
Unlike fecal transplants, which require use of donors and are an untargeted, inherently variable procedure, bacterial consortia therapeutics are defined drug compositions produced from clonally isolated bacteria that can trigger targeted immune responses. And unlike reductionistic approaches such as single strain probiotics, they can robustly shift the gut ecosystem.
The Leading Platform for Development Bacterial Consortia Therapeutics
Our platform enables identification of defined bacterial consortia with drug-like properties and their manufacture to GMP standards.